Moderna (MRNA) Total Current Liabilities (2017 - 2026)

Moderna (MRNA) has 10 years of Total Current Liabilities data on file, last reported at $2.4 billion in Q1 2026.

• On a quarterly basis, Total Current Liabilities rose 49.31% year-over-year to $2.4 billion in Q1 2026; TTM through Mar 2026 was $2.4 billion, a 49.31% increase from a year earlier, with the FY2025 full-year figure at $2.0 billion, down 9.93% from the prior year.
• Total Current Liabilities for Q1 2026 stood at $2.4 billion, up from $2.0 billion in the prior quarter.
• Over the last five years, Total Current Liabilities for MRNA reached as high as $9.2 billion in Q1 2022 and fell as low as $1.6 billion in Q2 2025.
• Historically, Total Current Liabilities has averaged $3.5 billion across 5 years, with a median of $2.4 billion in 2026.
• Across the five-year window, Total Current Liabilities tumbled 62.12% in 2023 and soared 49.31% in 2026, its largest moves.
• Year by year, Total Current Liabilities stood at $4.9 billion in 2022, then sank by 38.76% to $3.0 billion in 2023, then slipped by 26.83% to $2.2 billion in 2024, then slipped by 9.93% to $2.0 billion in 2025, then gained by 20.53% to $2.4 billion in 2026.
• Per Business Quant data, the three most recent Total Current Liabilities figures were $2.4 billion in Q1 2026, $2.0 billion in Q4 2025, and $1.7 billion in Q3 2025.